What question did this study set out to answer?

To analyze the presenting features and outcomes of patients with cold agglutinin disease (CAD) at a referral center.

December 8, 2025BloodOpen Access

Real world outcomes of patients with cold agglutinin disease

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows treatment options improved outcomes in cold agglutinin disease patients with significant haemolysis.

To analyze the presenting features and outcomes of patients with cold agglutinin disease (CAD) at a referral center.
Retrospective analysis of patients with CAD from 2016-2023 at a specialist center.
Collected baseline laboratory findings, clinical features, treatment, and survival data.
Response defined as stable increase in haemoglobin of >20 g/L or to normal without transfusion.
Fifty-four patients analyzed with a median age of 67 years at diagnosis.
Overall survival at 3 years was 93%, and 5 years was 86%.
Rituximab-based therapies achieved the highest response rates of 71%.

Japzon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark